Key takeaways
- MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA; SLU-PP-332 is a small synthetic molecule, C18H14N2O2, with no amino acids, so it is not a peptide.
- Studies that gave either compound used cells and animals (rodents for MOTS-c, mice for SLU-PP-332); these are not evidence of an effect in people.
- We found no published study that gave MOTS-c or SLU-PP-332 to people (21 Nov 2026); a placebo-controlled phase 2 trial of MOTS-c is recruiting, and ClinicalTrials.gov lists none for SLU-PP-332.
- FDA staff reviewed MOTS-c in 2026 and found “a lack of evidence to evaluate the effectiveness” for the uses nominated to them; we found no FDA review of SLU-PP-332.
- WADA has named MOTS-c in class S4.4.1 since the 2025 List; the 2027 List, in force from 1 January 2027, adds SLU-PP-332 to the same class, prohibited at all times.
01MOTS-c vs SLU-PP-332 in one table
The same questions for both, dated 21 November 2026.
| Question | MOTS-c | SLU-PP-332 |
|---|---|---|
| What it is | A peptide of 16 amino acids, encoded in mitochondrial DNA inside the 12S rRNA gene; described in 2015 | Not a peptide. A small synthetic molecule, C18H14N2O2, designed as an agonist of the estrogen-related receptors ERRα, ERRβ and ERRγ; reported in a 2023 paper |
| Made by the body | Yes; researchers have measured it in blood and muscle | No; it was designed and made in a laboratory |
| Studies that gave it | Rodents and cells (T3, T4) | Mice and cells (T3, T4) |
| Human studies | None published that gave it to people; studies in people measured the body’s own levels (T2). A registered phase 2 trial is recruiting, with no results | None found, published or registered. Laboratory work used human cells and human liver preparations |
| Regulator review of the evidence | FDA staff, 2026: “a lack of evidence to evaluate the effectiveness” for the uses nominated to them | We found none |
| United States | Drugs@FDA lists no product. In FDA’s compounding Category 2 from 29 Sep 2023 to 22 Apr 2026; named in HHS’s October 2026 draft policy, which “is not binding” | Drugs@FDA lists no product. Not named on FDA’s 503A nomination list (updated 14 May 2026), on its compounding safety-risk page or in the HHS policy |
| United Kingdom | No results on the emc medicines database (21 Nov 2026) | No results on the emc medicines database (21 Nov 2026) |
| Australia | Not named in the Poisons Standard October 2026; we draw no scheduling conclusion of our own | Not named in the Poisons Standard October 2026; we draw no scheduling conclusion of our own |
| Sport (WADA) | Named in class S4.4.1, metabolic modulators, since the 2025 List; prohibited at all times | Not named in the 2026 List. Named in class S4.4.1 of the 2027 List, in force 1 Jan 2027; prohibited at all times |
If you searched “slu-pp-332 vs mots-c”, the first difference is the class of molecule: one is a peptide the body makes, the other is a laboratory compound that is not a peptide. Everything about MOTS-c on its own: the MOTS-c guide.
02How do MOTS-c and SLU-PP-332 differ as molecules?
Three differences that a lab, a regulator and a reader can check. Each card shows one.
A peptide of 16 amino acids
A chain of amino acids encoded in mitochondrial DNA. PubChem lists it at 2,174.6 g/mol.
Not a peptide
A small synthetic molecule with no amino acids. PubChem lists it at 290.3 g/mol, less than a seventh of MOTS-c’s mass (our calculation from PubChem).
Different proposed targets
Cell work proposed AMPK, a cell energy sensor, for MOTS-c; FDA staff say its molecular target “remains unknown”. SLU-PP-332 was designed to bind the ERR receptors.
How a lab tells them apart. By mass, as the cards show. A purity percentage alone cannot show which compound a vial holds; the identity result on that lot’s report can.
03What have studies of each measured, and in which models?
One row per study cited here. Rows name the model and what was measured, not what to expect. Animal and cell findings are not evidence of an effect in people.
| Compound | Study | Model and n | What was measured | Tier |
|---|---|---|---|---|
| MOTS-c | Lee et al., 2015 | Cells and mice; the paper that described MOTS-c | Cell metabolism, the folate cycle and AMPK activity; insulin response in mice | T4, T3 |
| MOTS-c | Reynolds et al., 2021 | Mice aged 2, 12 and 22 months, 5 to 19 per group; a late-life cohort of 18 given MOTS-c and 19 control male mice | Treadmill performance; grip strength, stride length and a 60-second walking test | T3 |
| MOTS-c | Reynolds et al., 2021 | 10 young men who cycled; nothing was given to them | The body’s own MOTS-c in muscle and blood before and after exercise | T2 |
| SLU-PP-332 | Billon et al., 2023 | A mouse muscle cell line; male mice, 6 per group in the treadmill test | Cell respiration; running time and distance on a treadmill; grip strength; muscle fibre types | T4, T3 |
| SLU-PP-332 | Wang et al., 2023 | Mice aged 21 months, given it for 8 weeks | Kidney measures, including mitochondrial function and signalling proteins | T3 |
| SLU-PP-332 | Xu et al., 2024 | Mice with surgically induced pressure overload of the heart; heart cells | Heart function on ultrasound, gene activity, metabolite profiles | T3, T4 |
| SLU-PP-332 | Bonanni et al., 2025 | Muscle cells grown from biopsies of 10 women | Protein expression and cell measures in the dish | T4 |
Who did the work. The two MOTS-c mouse studies come from the group that described it; in 2021, two of its members declared consulting roles and shares in CohBar, Inc. Most SLU-PP-332 papers come from the group that designed it; in 2023, three authors declared stock in Myonid Therapeutics, “which focuses on ERR based therapeutics”. Material sold online is not the product these studies tested. T2 is small or uncontrolled human research, T3 animal studies and T4 cell studies: how we grade evidence.
04Has either been given to people in a study?
Not in any published study we found (PubMed and ClinicalTrials.gov, 21 November 2026). One trial of MOTS-c is registered; none of SLU-PP-332 is.
- 2015MOTS-c described
A University of Southern California group reports a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene, from cell and mouse work.
- 2021MOTS-c measured in people
Its own levels are measured before and after exercise in 10 young men; nothing is given to them.
- 2023SLU-PP-332 reported
Researchers in St. Louis report a synthetic ERR agonist and test it in cells and mice.
- Feb 2026A MOTS-c trial starts
NCT07505745, a randomised, placebo-controlled phase 2 trial planned for 120 patients aged 18 to 65, no healthy volunteers. It asks whether an insulin-sensitivity index and adverse events differ from placebo.
- 2026Anti-doping labs map SLU-PP-332
Laboratories in Cologne and Los Angeles describe its breakdown products, made with human liver preparations in the lab, for doping control. No person is given the compound.
- Nov 2026No results, no SLU-PP-332 trial
The MOTS-c trial is recruiting with no results. ClinicalTrials.gov lists no record for SLU-PP-332, and none of its 11 PubMed records describes giving it to people.
For MOTS-c, FDA staff wrote in 2026 that they “did not identify data, such as clinical studies, evaluating the administration of MOTS-c to humans”. Everything else on MOTS-c in people: the MOTS-c guide.
05Where do MOTS-c and SLU-PP-332 stand with regulators and in sport?
Regulators have reviewed one of the two. Status, dated 21 November 2026.
- 29 Sep 2023MOTS-c enters FDA Category 2
FDA’s list of compounding substances that may present significant safety risks. We found SLU-PP-332 on no FDA compounding list.
- 1 Jan 2025WADA names MOTS-c
In class S4.4.1, metabolic modulators, among activators of AMPK.
- 22 Apr–Jul 2026MOTS-c leaves Category 2 and is reviewed
HHS records that neither the placement nor the removal changed its status under section 503A, that FDA staff recommended against listing it, and that the July 2026 advisory committee voted in favour.
- 30 Oct 2026HHS draft policy
It names MOTS-c among six peptides; the notice calls it a draft that “is not binding”.
- 1 Jan 2027WADA names SLU-PP-332
The 2027 List adds “SLU-PP-332, SLU-PP-915 and related substances” to class S4.4.1, “as examples of metabolic modulators acting particularly on oxidative metabolism”, in the words of WADA’s explanatory note.
Safety statements, and for which compound. FDA’s compounding page says drugs containing MOTS-c “may pose significant risk for immunogenicity for certain routes of administration” and that FDA “has not identified any human exposure data” on them. We found no FDA statement on SLU-PP-332 either way, so the absence of one says nothing about its safety.
UK and Australia. Neither name returned a result on the emc database (21 November 2026), which is not the full UK register. Neither is named in Australia’s Poisons Standard October 2026; we draw no scheduling conclusion of our own. For peptides, the TGA says that “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” Sport, in detail: is MOTS-c banned in sport?
06What we don’t know about MOTS-c and SLU-PP-332
Whether either does anything in people
We found no published study that gave MOTS-c or SLU-PP-332 to people (PubMed and ClinicalTrials.gov, 21 Nov 2026). The one registered MOTS-c trial has no results.
Whether mouse results carry over
Every study that gave either compound used cells or animals: rodents for MOTS-c, mice for SLU-PP-332. FDA staff call the clinical relevance of the MOTS-c animal findings “currently unknown”.
How the body handles either one
FDA staff identified no human exposure data for MOTS-c. For SLU-PP-332, the human data we found are breakdown products made in the lab from liver preparations.
Which compound a vial holds
The two differ more than sevenfold in mass (our calculation from PubChem). Only the identity result on that lot’s report shows which compound a sample is.
How to find the identity line on a lab report: how to read a COA.
This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.